Author(s): Firriolo FJ, Hupp WS
Abstract Share this page
Abstract Warfarin has been the primary anticoagulant drug used in the USA for more than 50 years. However, 2 novel types of oral anticoagulants have recently been approved for use in the USA. These are direct thrombin inhibitors (e.g., dabigatran etexilate) and factor Xa inhibitors (e.g., rivaroxaban). Dental health care providers may soon encounter patients who are being prescribed these medications. This article describes the pharmacologic properties and medical uses of these new oral anticoagulants. Also discussed are implications for the management of dental patients being treated with these new oral anticoagulants, including potential interactions with drugs commonly used or prescribed in the course of dental treatment. Copyright Â© 2012 Elsevier Inc. All rights reserved.
This article was published in Oral Surg Oral Med Oral Pathol Oral Radiol
and referenced in Journal of Blood Disorders & Transfusion